Cox regression survival analysis |
Peak cTnI level (per 10-fold increase) | 1.75 (1.43–2.14) | 1.70 (1.38–2.10) |
Tertiles of peak cTnI level |
Highest tertile (median 1827.1 pg/mL, quartiles 1097.0, 7885.9) | 4.05 (2.45–6.70) | 3.78 (2.26–6.34) |
Middle tertile (median 221.1 pg/mL, quartiles 159.6, 332.5) | 2.53 (1.52–4.22) | 2.51 (1.49–4.22) |
Lowest tertile (median 42.6 pg/mL, quartiles 30.4, 54.1) | 1 (Ref.) | 1 (Ref.) |
Age (per additional year) | NA | 1.01 (0.996–1.03) |
Female | NA | 0.74 (0.50–1.10) |
Treatment with QT-prolonging medications | NA | 1.04 (0.69–1.57) |
Cox regression survival analysis |
Initial cTnI level (per 10-fold increase) | 1.41 (1.14–1.76) | 1.32 (1.06–1.66) |
Age (per additional year) | NA | 1.01 (0.996–1.03) |
Female | NA | 0.55 (0.37–0.8) |
Treatment with QT-prolonging medications | NA | 1.04 (0.69–1.57) |
Logistic regression model of IMV support |
Peak cTnI level (per 10-fold increase) | 2.77 (1.82–4.40) | 3.02 (1.92–4.98) |
Age (per additional year) | NA | 0.99 (0.96–1.01) |
Female | NA | 1.17 (0.59–2.36) |
Treatment with QT-prolonging medications | NA | 1.10 (0.52–2.32) |